Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04510077 · ClinicalTrials.gov registry record · NA
SmartQuit Program for Smoking Cessation
A NA study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 99
- Enrollment target
NCT04510077: Completed NA study, sponsored by Fred Hutchinson Cancer Center.
NCT04510077 is a NA study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 99 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04510077, a NA study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 99 participants
- Enrollment target
Study Summary
This trial investigates how well a smartphone-based smoking cessation program called SmartQuit works to help patients stop smoking. SmartQuit is an smartphone application-based smoking cessation program that includes a defined program consisting of interactive evidence-based exercises for dealing more effectively with urges to smoke, a place to track desired behaviors, personalized plans for quitting, and a certificate of completion once the recommended program components are completed. SmartQuit may help patients quit smoking, lower healthcare costs and reduce premature tobacco-related deaths.
Primary Outcome
No smoking at all in the past 7 or more days (7-day point prevalence quit rate).
Interventions
- OTHER Survey Administration
- BEHAVIORAL SmartQuit Smoking and Tobacco Cessation Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2014-10-22 |
| Est. Completion | 2015-08-11 |
| Phase | NA |
What the finished NCT04510077 record still lists
NCT04510077 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Survey Administration is the first listed.
NCT04510077 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04510077 about?
NCT04510077 is a clinical study titled "SmartQuit Program for Smoking Cessation". This trial investigates how well a smartphone-based smoking cessation program called SmartQuit works to help patients stop smoking. SmartQuit is an smartphone application-based smoking cessation program that includes a defined program consisting of interactive evidence-based exercises for dealing mo...
What is the current status of trial NCT04510077?
This trial is currently completed. It is a NA study. The enrollment target is 99 participants. The study started on 2014-10-22. Estimated completion is 2015-08-11.
What interventions are being tested in trial NCT04510077?
The interventions under investigation include: Survey Administration (OTHER), SmartQuit Smoking and Tobacco Cessation Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT04510077?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04510077's enrollment target sits among peer trials
99 920th of 2000 higher than 1,079 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI